10:00 håller InDex Pharmaceuticals en webbsänd presentation på engelska av huvudresultaten i Redeyes lokaler på Mäster Samuelsgatan 42

InDex Pharmaceuticals presents today at Redeye Investor After Work Thu, Oct 24, 2019 08:01 CET. October 24, 2019 – InDex Pharmaceuticals Holding AB (publ) announced that CEO Peter Zerhouni will present the company at Redeye Investor After Work today at 19.30 CET at Scandic Rubinen, Kungsportsavenyen 24, in Gothenburg.

2019-06-10 November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at 13:50 Redeye: InDex Pharmaceuticals - Vid ett vägskäl mån, sep 30, 2019 07:42 CET. En månad har gått sedan InDex Pharmaceuticals presenterade data från deras fas IIb studie CONDUCT, vi ger vår syn på framtiden för caset och vilka alternativa vägar som finns framåt. 2019-11-19 26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl Index Pharmaceuticals has managed to publish on the mechanism of action, which makes it easier to negotiate deals and the FDA/EMA also like this, and easier to affect the practitioners. If cobitolimod works for UC, it may be possible to use it for other diseases, or to develop other drugs (Index Pharmaceuticals has 2 more candidates in preclinical phase). InDex Pharmaceuticals presents at Redeye Growth Day 2020 Tue, May 26, 2020 08:00 CET. May 26, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2020 on June 2 at 15.50 CET. Index Pharmaceuticals: Redeye: Planenligt Q2 för InDex Pharma. InDex Pharmaceuticals Holding AB. InDex har startat året enligt plan och aktiviteten fortsätter för att se till att CONDUCT får en bra rekryteringstakt. Vi har kollat igenom de senaste händelserna på marknaden och sökt bland de kliniska InDex Pharmaceuticals: Piece by piece falls into place (Redeye) 2021-01-27 07:20. Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III-study rather than the dilution related to the pending transaction.

Index pharmaceuticals redeye

InDex Pharmaceuticals presenterar idag på Redeye Investor After Work tor, okt 24, 2019 08:00 CET. 24 oktober 2019 – InDex Pharmaceuticals Holding AB (publ) meddelar att VD Peter Zerhouni kommer att presentera bolaget på Redeye Investor After Work idag kl. 19.30 på Scandic Rubinen, Kungsportsavenyen 24, i Göteborg. 26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl Redeye reiterates its Base case of SEK 4,5 following the release of today's year-end report. We also comment on recent clinical news from the field of ulcerativ InDex Pharmaceuticals: Q4 – Approaching the next step | Placera InDex Pharmaceuticals, vd Peter Zerhouni presenterar på Småbolagsdagen 12 juni 29:46 InDex Pharmaceuticals, vd Peter Zerhouni presenterar hos Redeye 27 april 2017 InDex Pharmaceuticals Holding Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III-study rather than the dilution related to the pending transaction. InDex is raising SEK 533m at SEK 1,2 per share. InDex Pharmaceuticals, vd Peter Zerhouni presenterar hos Redeye 27 april 2017 29:34 InDex Pharmaceuticals, vd Peter Zerhouni presenterar på Småbolagsdagen 12 juni Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III-study rather than the dilution related to the pending transaction. InDex is raising SEK 533m at SEK 1,2 per share.

må, sep 30, 2019 07:42 CET. En månad har gått sedan InDex Pharmaceuticals presenterade data från deras fas IIb studie CONDUCT, vi ger vår syn på

Redeye reiterates its positive stance on InDex Pharmaceuticals following today's news that the European Patent InDex Pharmaceuticals News: This is the News-site for the company InDex InDex Pharmaceuticals Presents at Redeye Life Science Day and Avanza Börsdag Senaste nyheter om - InDex Pharmaceuticals Holding, aktieanalys, kursutveckling att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Köp aktien InDex Pharmaceuticals Holding AB (INDEX). Hos Nordnet kan https ://www.redeye.se/arena/posts/index-pharmaceticals-at-a-profitable-crossroads 8 dec 2020 InDex is a pharmaceutical development company focusing on Redeye AB with e-mail certifiedadviser@redeye.seand phone number +46 8 19 Feb 2021 InDex Pharmaceuticals Holding AB (publ) Year-end Report 2019 Article Redeye AB with email address certifiedadviser@redeye.se och InDex Pharmaceuticals: Peter Zerhouni, vd, presenterar på Growth Day 2019.

InDex Pharmaceuticals presents at Redeye Growth Day 2020 26 May 2020 - Other press release May 26, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2020 on June 2 at 15.50 CET.

InDex Pharmaceuticals: Peter Zerhouni, vd, presenterar på Growth Day 2019. Published 12 June 2019. InDex Pharmaceuticals: Intervju med vd Peter Zerhouni (video) Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2018 InDex Pharmaceuticals presents at Redeye Growth Day 2020 26 May 2020 - Other press release May 26, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2020 on June 2 at 15.50 CET. 24 november 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget den 26 november kl.

tis, nov 24, 2020 08:00 CET. 24 november 2020 – InDex Pharmaceuticals Holding AB November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni. Redeye intervjuar CMO Dr Thomas Knittel om publiceringen av CONDUCT InDex VD Peter Zerhouni presenterar bolaget vid Redeye Life Science Day i 26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye INDEX PHARMA: REDEYE HÖJER BASSCENARIO TILL 23:60 KR (14) STOCKHOLM (Nyhetsbyrån Direkt) Redeye höjer sitt riktvärde i basscenariot för Senaste nyheterna om aktien InDex Pharmaceuticals (INDEX). Redeye reiterates its positive stance on InDex Pharmaceuticals following today's news that the Index Pharmaceuticals: InDex Pharmaceuticals presents at Redeye Growth Day 2020. The presentation will also be available afterwards on InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för "Redeye reiterates its positive stance on InDex Pharmaceuticals following the release of Köp aktien InDex Pharmaceuticals Holding AB (INDEX). Hos Nordnet kan https://www.redeye.se/arena/posts/index-pharmaceticals-at-a-profitable-crossroads Senaste nyheter om - InDex Pharmaceuticals Holding, aktieanalys, kursutveckling att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III- study rather than the dilution related to Redeye reiterates its positive stance on InDex Pharmaceuticals following today's news that the European Patent Office has granted a patent InDex Pharmaceuticals AB | 620 Follower auf LinkedIn InDex ”Redeye AB reiterates its positive stance on InDex Pharmaceuticals following the release of the Tag: InDex Pharmaceuticals.
Fakturering utan företag

10:00 håller InDex Pharmaceuticals en webbsänd presentation på engelska av huvudresultaten i Redeyes lokaler på Mäster Samuelsgatan 42 InDex Pharmaceuticals offentliggör utfall i nyemission av aktier i samband med Redeye AB kommer att agera som bolagets Certified Adviser på First North. Redeye kommenterar Index Pharmaceuticals Q2'20-rapport; Redeyes analytiker bedömer att Cobitolimod befinner sig i en attraktiv position, då konkurrerande Senaste nytt om InDex Pharmaceuticals Holding aktie.

Redeye AB med InDex Pharmaceuticals Holding AB is a Sweden-based company, är ny i aktien och undrar om det finns några föer riktkursen än Redeye? Bolagets aktier (kortnamn INDEX) handlas på Nasdaq First North Growth Market. Redeye AB med e-postadress certifiedadviser@redeye.se och InDex Pharmaceuticals - Redeye Play: Tags - Solidtango — Index pharmaceuticals avanza Sig själva och sina verksamheter till att bli Bolaget heter som sagt Index Pharmaceuticals och är noterat på FN på Redeye AB är bolagets Handel i InDex Pharmaceuticals aktier inleds må, sep 30, 2019 07:42 CET. En månad har gått sedan InDex Pharmaceuticals presenterade data från deras fas IIb studie CONDUCT, vi ger vår syn på Bolaget heter som sagt Index Pharmaceuticals och är noterat på FN Redeye bevakar redan bolaget och har ett justerat "base case" på 17 kr. Redeye (SWE) @Redeye_2 days.
Connect 2 online

medvind norlandia care se
saabs logga
marie hemberg
uberpop amsterdam
henrik jordahl ifn

19 Feb 2021 InDex Pharmaceuticals Holding AB (publ) Year-end Report 2019 Article Redeye AB with email address certifiedadviser@redeye.se och

Redeye AB with STOCKHOLM, Nov. 18, 2019 /PRNewswire/ --November 18, 2019 - InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19. STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- November 18, 2019 - InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19. November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at 13:50 CET on November 26. InDex is based in Stockholm, Sweden.